Lymphoma

The Lymphoma Program of the OHSU Center for Hematologic Malignancies is organized to provide a comprehensive evaluation of Hodgkin's Disease or Non-Hodgkin's Lymphoma as well as provide up-to-date information necessary to understand the ever-changing treatment options and outcomes. Lymphoma is a cancer of B or T lymphocytes. Lymphocytes are part of our immune system and are important in fighting infections. There are 2 main types of lymphoma, Hodgkin's and non-Hodgkin's lymphoma. Hodgkin's lymphoma is a relatively rare type of cancer and one of the most treatable and curable malignancies. Non-Hodgkin's lymphoma is more common type of lymphoma and it is affecting an increasing number of people. There are many subtypes of non-Hodgkin's lymphoma; some subtypes growing very quickly requiring urgent treatment and others that grow very slowly and can be watched for years before requiring treatment.

Over the past 10 years, there have been many advances in the treatment of lymphoma including using antibodies with chemotherapy. Tumor vaccines are also being developed for some type of lymphoma. Autologous or allogeneic transplantation is often considered for those patients with recurrent disease. It is now being considered as part of the initial treatment for patients with aggressive lymphoma who have a high risk of disease recurring after standard treatment.

During your visit, you will have the opportunity to learn about your disease, as well as be informed of the most promising new treatments. We work closely with our colleagues within the Division of Hematopathology and Laboratory of Cytogenetics to provide you with a comprehensive to provide world-class molecular diagnosis. We have members of our faculty who lead the country in research on the molecular basis of lymphoma as well as developing new treatments strategies. We have a number of new molecular based therapeutics available on clinical trials for patients with lymphoma . As well, we have clinical trials that utilize blood or marrow transplants after high dose chemotherapy. Our team of lymphoma experts continues to actively develop new treatment options for patients with Non Hodgkin's Lymphoma, which will hopefully lead to better and longer lives for our patients with reduced side effects of treatment.

Treating Physicians:
Brandon Hayes-Lattin, M.D.
Michael Deininger, M.D., Ph.D.
Craig Okada, M.D., Ph. D.
Richard Maziarz, M.D., Transplantation Director

Make an Appointment

Clinical Trials Related to this Disease